Sam Butterworth

Sam Butterworth

Dr, Dr

  • Senior Lecturer in Medicinal Chemistry, Pharmacy
If you made any changes in Pure these will be visible here soon.

Personal profile

Overview

Sam joined the university as a Senior Lecturer in Medicinal Chemistry in November 2016. Prior to this he worked at the University of Birmingham from 2013 and at AstraZeneca from 2005-2013. During this time he has been accountable for chemistry strategy and delivery for all phases of discovery projects through externalised pre-portfolio collaborations, HTS, Lead Generation, Lead Optimisation to Pre-clinical development. His work at AstraZeneca led to the development of a targeted anti-cancer agent AZD9291, that was approved by the FDA in November 2015 and is now used internationally under the name osimertinib/Tagrisso. Along with his colleagues Sam has been recognised for this work through the 2017 RSC Malcolm Campbell Award and the 2018 ACS Heroes of Chemistry award (see link above). 

The Butterworth group work on applying synthetic and biological chemistry to study and solve biological problems of relevance to human health and disease. All projects are conducted in collaboration with biomedical researchers and clinicians, allowing testing of compounds in the most relevant biological models. 

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Areas of expertise

  • QD Chemistry
  • RM Therapeutics. Pharmacology

Fingerprint

Dive into the research topics where Sam Butterworth is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or